Karus Therapeutics has announced that it has entered into a collaboration with the Babraham Institute (Cambridge, UK), to further characterize novel treatments for inflammatory diseases through the ...

Myriad of Groups Are Working on the Latest Hot Target and Most Are Optimistic About Its Potential Although the term “signal transduction” was coined back in 1972, cell-signaling switches have only ...

Gedatolisib targets HR+/HER2-, PIK3CA wild-type advanced breast cancer, with a PDUFA goal date of July 17, 2026. The drug's multi-target approach inhibits all four class 1 PI3K isoforms, mTORC1, and ...